A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT07205796 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: HZ Vaccine (IN001)
BIOLOGICAL: Shingrix

Sponsor

Shenzhen Shenxin Biotechnology Co., Ltd